

To prevent delays, complete all fields and **FAX ALL 4 PAGES** to **1-844-RAREFAX** (1-844-727-3329). For assistance, call us at **1-855-5VEOPOZ** (1-855-583-6769) Option 1, Monday–Friday, 9 AM–9 PM Eastern time.

Please make sure to fill out all the necessary information on pages 1 and 2, which is denoted by REQUIRED flags.

SECTION 1 Patient In	formation				REQUIRED		
Patient contact information atta	ached						
First name	Middle initial	Last name	DOB/_	/ Gender [] I	M F Prefer not to disclo		
Address		City	State		ZIP		
			OK to leave detailed message? Yes				
			OK to leave detailed message? Yes				
Patient's preferred language (if no				_			
			Alternate contact/Caregiver phone	e # ()			
Patient Consents I have read and agree to enroll in myRARE® Information included in Section 8	® for VEOPOZ and to the Authorization	on to Disclose/Use Health	I have read and agree to enroll in myRARE	For VEOPOZ and to the Patien	t Certifications included in Section §		
Sign (1 of 2)			Sign (2 of 2)				
Patient signature/Lega	al representative	Date (MM/DD/YYYY) Patient signature/Lega	al representative	Date (MM/DD/YYY		
Relationship to patient (if signed by	someone other than the pati	ent, please describe your a	authority to sign on behalf of the patient)				
SECTION 2 Patient In	surance Information				REQUIRED		
Does the patient have insurance (t	third-party or private insuran	ce)? Yes No (if no.	you can skip this question)				
Primary Insurance	. , ,	,	Secondary/Prescription Insuran	nce (if applicable)	Prescription insurance		
f copy of insurance card (front and	d back) is attached, check h	ere 🗌	If copy of insurance card (front and back) is attached, check here				
Primary insurance name			Secondary insurance name				
Primary insurance phone # (Secondary insurance phone # ()				
Policy #			Policy#	Policy # BIN #			
Group #				PCN #			
Policyholder name			Policyholder name				
Policyholder's relationship to patient			Policyholder's relationship to patient				
	ing Physician Information				REQUIRED		
Physician Information			Primary Office Contact				
Name			(Who myRARE should contact to	review patient coverage	. collect missing information.		
Practice/Facility name			and determine treatment setting a				
			Name				
Address City		7IP	Direct phone # ()	Fax			
			Email				
,		Preferred method of contact: Phone Email Fax					
National Practice Identifier (NPI) Tax ID # Tax ID #		Preferred day(s) of contact: Mon Tues Wed Thurs Fri					
Infusion Setting and Administrat	tion (Benefits will be provide	d based on indicated pref	rerences and patient's plan coverage.)				
Initial Loading Dose: Intravenous Infusion (one time)		Maintenance Dose: Subcutaneous Injection (weekly)					
Preferred Treatment Setting	Preferred Acquisition Char		Preferred Treatment Setting	Preferred Acquisition	Channel		
Home	Specialty pharmacy with ho	me infusion	Home	Specialty pharmacy wit	h home infusion		
Clinical setting	Buy-and-bill		Clinical setting	Buy-and-bill			
☐ In-office ☐ Infusion center	Specialty pharmacy to bi	<u> </u>	☐ In-office ☐ Infusion center	☐ Specialty pharmacy	to bill		
Undecided-Benefits information will be provided for available options based on plan coverage			Undecided-Benefits information will be provided for available options based on plan coverage				
Name of preferred site of infusion, if	different from practice/facility	name above					
A ddraga		*:+.,					

To prevent delays, complete all fields and FAX ALL 4 PAGES to 1-844-RAREFAX.

ZIP





To prevent delays, complete all fields and **FAX ALL 4 PAGES** to **1-844-RAREFAX** (1-844-727-3329). For assistance, call us at **1-855-5VEOPOZ** (1-855-583-6769) Option 1, Monday–Friday, 9 AM–9 PM Eastern time.

Patient name			Patient DOB/			
escriber name NPI #						
SECTION 4 Diagnosis/Prescription					F	REQUIRED
Diagnosis: ☐ CHAPLE disease (CD55-deficient protein-lo ICD-10-CM Diagnosis Code: D84.1 Defects in the complement	• . ,, =	ther				
REQUIRED Patient weight in kg □ Initial dose: Infusion prescription Rx: VEOPOZ™ (pozelimab-bbfg) injection Dose: 30 mg/kg IV one time Infusion rate: 25 mg/hour to 250 mg/hour Intended IV solution concentration: 6.7 mg/mL to 20 mg/	/mL	Infu [OR	refills usion fluid type (please) 0.9% saline injection 5% dextrose injection	nmL	• • • • • • • • • • • • • • • • • • • •	
☐ Ongoing: Subcutaneous dose prescription Rx: VEOPOZ™ (pozelimab-bbfg) injection Dose: 10 mg/kg subcutaneously weekly [Escalation dose: 12 mg/kg subcutaneously weekly]		30-	day supply Refills _			
SECTION 5 Physician Certification					F	REQUIRED
I confirm that I received and reviewed the Dear HCP Letter You have my permission to reach out to this patient to promise medically necessary for the patient identified on this form. I understand that it overify my patient's insurance coverage; to assess, if applicable, my patient's the myRARE Program. I certify that I have obtained my patient's written authorize regulations, to provide the individually identifiable health information on this for patient and to act on my behalf for the limited purpose of transmitting this presauthorized to transmit this prescription to a network pharmacy it selects. I certificated, bartered or distributed for sale. I understand that any free product distributed for sale.	ovide and review the Media ormation provided on this application my patient's information provided eligibility for patient assistance azation in accordance with application to treimbursement support procription to the appropriate pharm fy that VEOPOZ received free of ce product or related medical probuted through the myRARE Patie that Regeneron may revise, characteristics.	cation Guide and ation, to the best of m d to Regeneron Pharm and other support proyule and the state and federal grams such as myRA hacy designated by the charge from the myRA ocedures and services and services and services or terminate any	Patient Safety Card y knowledge, is complete an acceuticals, Inc., and its affili grams; and to otherwise adm law, including the Health Ins RE for these purposes. If appe patient per their benefit pla RE Patient Assistance Progres will be submitted to any pain is not contingent on any purpose.	ates and agents (togeth inister myRARE for the urance Portability and A licable, I authorize myR in provided that, if this p im in response to this a yer, including Medicare rchase obligations. I co	er, "Regeneron") is fi patient including fac ccountability Act of 1 ARE to conduct a beo prescription is not so pplication, if any, will and Medicaid; and n nsent to myRARE con	or the use of myRARE® solely illtating enrollment into 1996 and its implementing nefits investigation for my designated, myRARE is I be used exclusively for the o free product may be sold,
SECTION 6 Patient History						
Diagnosis (Genetic AND Clinical) Genetic: Confirmation of CD55 loss-of-function mutation Clinical: History of protein-losing enteropathy Age at diagnosis: History of hospitalizations in the past year? Yes No If YES, how many days? Previous and/or current treatments	Surgical resection of in Yes No History of blood clots? Yes No Family history of CHAF		Clinical symptoms Abdominal pain Diarrhea Facial edema Nausea Peripheral edema Vomiting	Serum albur Immunoglob Vitamin B12	min levels (g/dL) pulin levels (mg/	dL)
Treatment name	Start date /	St //	/	Current	Intolerant	Resistant
					•	

CHAPLE=CD55 deficiency with hyperactivation of complement, angiopathic thrombosis and protein-losing enteropathy; ICD-10-CM=International Classification of Diseases, Tenth Revision, Clinical Modification; IV=intravenous.

To prevent delays, complete all fields and FAX ALL 4 PAGES to 1-844-RAREFAX.

Please see accompanying full <u>Prescribing Information</u>, including Boxed WARNING, and Medication Guide. 07/2023 VEO.23.04.0003



To prevent delays, complete all fields and **FAX ALL 4 PAGES** to **1-844-RAREFAX** (1-844-727-3329). For assistance, call us at **1-855-5VEOPOZ** (1-855-583-6769) Option 1, Monday–Friday, 9 AM–9 PM Eastern time.

Patient name	Patient DOB/
Prescriber name	NPI #
SECTION 7	Financial Information (must be completed for Patient Assistance Program [PAP] requests)
, , ,	re in your household? What is your total annual household income?*

To qualify for the myRARE® Patient Assistance Program, I understand that I must meet certain income and other eligibility requirements. myRARE may ask for proof of income at any time for the purpose of audit/verification. If requested, I agree to provide proof of income within thirty (30) days of the request. Continuation in the program is conditioned upon timely verification of income. In addition, I agree to notify myRARE promptly if my insurance situation changes. I also agree that Regeneron Pharmaceuticals, Inc. and its affiliates, representatives, agents and contractors (together, "Regeneron") may verify my eligibility for the myRARE Program, and I understand that such verification may include contacting me or my healthcare provider for additional information and/or reviewing additional financial, insurance, and/or medical information. I authorize Regeneron to use my Social Security number and/or additional demographic information to access reports on my individual credit history from consumer reporting agencies for purposes of determining my income eligibility. I understand that, upon request, Regeneron will tell me whether an individual consumer report was requested and the name and address of the agency that furnished it. I further understand and authorize Regeneron to use any consumer reports about me and information collected from me, along with other information they obtain from public and other sources, to estimate my income in conjunction with the Patient Assistance Program eligibility determination process.

[Patients whose benefits include the use of an Alternate Funding Program are not eligible for Alliance Patient Assistance Programs/need-based free drug. Patients with insurance plans or employers who sign up with these alternate funding vendors will have no coverage for specialty drugs that are identified on a list determined by the alternate funding vendor and will be required to apply to a manufacturer patient assistance program or pursue specialty drugs, including Alliance products. I agree to inform the Alliance Patient Assistance Program team if I am a member of such an insurance plan or if I am applying to an Alliance Patient Assistance Program on behalf of a patient who is a member of such an insurance plan. Further, the Alliance Patient Assistance Program team may take additional steps to verify the patient assistance Program for either myself or on behalf of a patient, I authorize the Alliance Patient Assistance Program team to contact my/the patient's employer, insurer, and other third parties (such as pharmacy benefit managers and their affiliated partners) to verify prescription benefit design and coverage.]

SECTION 8

Authorization to Disclose/Use Health Information

Please read the following carefully, then date and sign where indicated in Section 1 on page 1.

I authorize my healthcare providers and staff ("Health Care Providers"), my health insurer, health plan or programs that provide me healthcare benefits (together, "Health Insurers"), and any specialty pharmacies ("Specialty Pharmacies") that dispense my medication to disclose to Regeneron Pharmaceuticals, Inc., and its affiliates and agents (together, "Regeneron") health information about me, including information related to my medical condition, treatment with VEOPOZ, health insurance coverage, claims, prescription, and referral to and enrollment in the myRARE Program (together, "My Information"). My Health Care Providers, Health Insurers, Specialty Pharmacies, and Regeneron may use and disclose My Information for the purposes of providing certain support services, including:

- To determine if I am eligible to participate in myRARE reimbursement and coverage assistance program(s), Patient Assistance Programs, and other support programs (together, "myRARE Program");
- For the operation and administration of the myRARE Program;
- To investigate my health insurance coverage benefits;
- To obtain prior authorization for coverage/reimbursement;
- To assist with appeals of denied claims for coverage/reimbursement; and
- To refer me to, or to determine eligibility for, other programs and/or alternate sources of funding—such as Medicaid, healthcare exchanges, Medigap, state pharmaceutical assistance programs (SPAPs), and charitable foundations—that may be available to provide assistance to me with the costs of my medications.

I understand and agree that my Health Care Providers, Health Insurers, and Specialty Pharmacies may receive remuneration from Regeneron in exchange for disclosing My Information to Regeneron and/or for providing me with support services in connection with VEOPOZ or the myRARE Program. Once My Information has been disclosed to Regeneron, I understand that federal privacy laws may no longer protect it from further disclosure. However, Regeneron has agreed to protect My Information by using and disclosing it only for the purposes authorized in this Authorization or as otherwise required by law. I understand that I may be contacted by Regeneron in the event that I report an adverse event. I understand that if I refuse to sign this, I will not be able to participate in the myRARE Program, but it will not affect my eligibility to obtain medical treatment, my ability to seek payment for this treatment, or my insurance enrollment or eligibility for insurance coverage. Furthermore, I understand that I may withdraw (take back) this Authorization at any time by mailing, faxing, or emailing a written request to myRARE at 1107 Nicholas Blvd, Elk Grove Village, IL 60007; fax: 1-844-RAREFAX (1-844-727-3329); email: unsubscribe@regeneron.com. Withdrawal of this Authorization will end further uses and disclosures of My Information based on this Authorization made before my request is received and processed by my Health Care providers, Health Insurers, and Specialty Pharmacies. This Authorization expires 18 months from the date support is last provided under any myRARE Program, subject to applicable law, unless I withdraw it earlier. I understand that I may request a copy of this Authorization.



To prevent delays, complete all fields and **FAX ALL 4 PAGES** to **1-844-RAREFAX** (1-844-727-3329). For assistance, call us at **1-855-5VEOPOZ** (1-855-583-6769) Option 1, Monday–Friday, 9 AM–9 PM Eastern time.

Patient name	Patient DOB	/	/
Prescriber name	NPI #		

 $\langle \rangle$

SECTION 9

Patient Certifications

Please read the following carefully, then date and sign where indicated in Section 1 on page 1.

I am enrolling in the myRARE® Program (the "Program") and authorize Regeneron Pharmaceuticals, Inc., and its affiliates, representatives, agents and contractors (together, "Regeneron") to provide services to me under the Program, as described in the Program Enrollment Form, such as coverage and reimbursement support, financial assistance, nurse education, and other support programs (the "Services"). I agree to my enrollment in the myRARE Copay Program if confirmed as eligible, understand that copay information will be sent to my physician or the designated specialty pharmacy, and understand that any assistance with my applicable cost-sharing or copayment for VEOPOZ will be made in accordance with the Program terms and conditions. If I am applying for the Patient Assistance Program (PAP), I confirm my agreement with the conditions set forth, and certify that the number of people in my household and my household income are true and accurate to the best of my knowledge. If I am approved for the PAP, I certify that no claim for reimbursement will be submitted to any third-party payer for product I receive at no cost while I am enrolled in the Program. If I am enrolled in a Medicare Prescription Drug Plan, I acknowledge that the value of any free product I receive cannot be counted toward my True Out-of-Pocket (TrOOP) expenses and that Regeneron will notify my plan of the assistance received through the PAP. I authorize Regeneron to contact me by mail, telephone, email, or if I indicated my agreement and consent on page 1, with information about the Program, my condition, promotions related to VEOPOZ, brand opportunities, services, and research studies, and to ask my opinion about such information and topics, including market research and disease-related surveys. I further authorize Regeneron to use my de-identified information for performing research, education, business analytics, marketing studies, or for other commercial purposes, including linkage with de-identified information about you from other sources (e.g., electronic health records, insurance and billing data, mobile devices, and genomic information) for research and analytics activities. As described in the Authorization to Disclose/ Use Health Information, I understand that members of Regeneron may share health information about me, including information related to my medical condition, treatment with VEOPOZ, health insurance coverage, claims, prescription, and referral to and enrollment in the Program (together, "My Information"), with one another for these purposes and as needed to perform the Services or to send the communications listed above (the "Communications"). I understand and agree that Regeneron may use my health information for these purposes and may share My Information with my health care providers and staff (together, "Health Care Providers"), my health insurer, health plan or programs that provide me healthcare benefits (together, "Health Insurers"), and any specialty pharmacies ("Specialty Pharmacies") that dispense my medication. I understand that I do not have to enroll in the Program or receive the Communications, and that I can still receive VEOPOZ, as prescribed by my Health Care Providers. I may opt out of receiving Communications, individual support services offered by the Program, including the myRARE Copay Program, or opt out of the Program entirely, at any time by notifying a Program representative by: calling 1-855-5VEOPOZ (1-855-583-6769); sending a letter to myRARE, 1107 Nicholas Blvd, Elk Grove Village, IL 60007; faxing 1-844-RAREFAX (1-844-727-3329); or emailing unsubscribe@regeneron.com. I also understand that the Services may be revised, changed, or terminated at any time.

Other information about privacy practices

I understand that my health information, contact information, and other information that I, my healthcare provider, and others share with Regeneron Pharmaceuticals, Inc., and its affiliates and agents (together "Regeneron") is collected to provide me with the assistance I request and for other Regeneron business purposes, as described in its privacy notice, which is available at regeneron.com/privacy-notice. Depending on where I live, I may have certain rights with respect to my personal information, including the request to access or delete my personal information. I am aware that Regeneron may not be required to fulfill my requests in certain circumstances. I understand that to exercise these rights, I may contact the Privacy Office by emailing dataprotection@regeneron.com or by calling 1-844-835-4137.

You may keep a copy of this form for your records.

Please see accompanying full Prescribing Information, including Boxed WARNING, and Medication Guide.

For any questions or concerns, or to report side effects with a Regeneron product while enrolled in myRARE, please contact us at **1-855-5VEOPOZ** (1-855-583-6769) Option 1, Monday–Friday, 9 AM–9 PM Eastern time.



